Pharmacological treatment of heterotopic ossification following hip and acetabular surgery

Heterotopic ossification is a common complication following total hip arthroplasty and surgery following acetabular trauma. It is associated with pain and a decreased range of movement. Prophylaxis is achieved by either non-steroidal anti-inflammatory drug treatment or localised irradiation therapy. The objective of this study was to evaluate the evidence for pharmacological agents used for the prophylaxis of heterotopic ossification following hip and acetabular surgery. The study used a comprehensive literature search to identify all major clinical studies investigating the pharmacological agents used in the prophylaxis of heterotopic ossification following hip and acetabular surgery. It was concluded that indometacin remains the 'gold standard' for heterotopic ossification prophylaxis following total hip arthroplasty and is the only drug proven to be effective against heterotopic ossification following acetabular surgery. Following total hip arthroplasty, other non-steroidal anti-inflammatory drugs, including naproxen and diclofenac, are equally as effective as indometacin and can be considered as alternative first-line treatments. Celecoxib is also of equal efficacy to indometacin and is associated with significantly fewer gastrointestinal side effects. However, serious concerns were raised over the safety of selective cyclooxygenase-2 inhibitors for the cardiovascular system and these should be used cautiously.     

Early postoperative bleeding in polytrauma patients treated with fondaparinux: literature review and institutional experience

Surgery for pelvic or acetabular fractures carries a high risk of deep-vein thrombosis (DVT). Reports indicate that fondaparinux is a more effective thromboprophylactic agent than low molecular weight heparin (LMWH) after major orthopaedic surgery. The safety and efficacy of fondaparinux was evaluated in a new protocol used for DVT prophylaxis. One hundred and twenty seven patients with pelvic or acetabular fractures received either fondaparinux or enoxaparin and were analysed in a historical non-concurrent study. Specific review points included clinical deep-vein thrombosis (DVT) or pulmonary embolism (PE) and evidence of adverse effects such as bleeding or allergic reactions. Two patients that received enoxaparin were found to have a DVT and one patient had a PE. There was no documented DVT or PE in patients that received fondaparinux. The mean number of units of blood transfused postoperatively was higher in the enoxaparin group; however, multivariate regression modelling demonstrated no significant difference between the groups. The most current large randomised controlled studies investigating the administration of fondaparinux following joint arthroplasty or hip fracture surgery, have demonstrated a slight increase or a similar number of bleeding events in patients treated with fondaparinux when compared to those treated with enoxaparin. The current report supports that fondaparinux, in patients with pelvic and acetabular fractures, can be equally effective as enoxaparin and not associated with adverse bleeding events.     

Sclerostin monoclonal antibodies on bone metabolism and fracture healing

Introduction: The biological enhancement of fracture healing may prevent complications such as non-union and revision surgery. Sclerostin is produced by osteocytes and binds to the LRP5/6 receptor. This inhibits the Wnt signalling pathway and thereby reduces bone formation. Areas covered: Targeted deletion of the sclerostin gene has been found to enhance bone formation and fracture healing in rodent models. A number of in vivo studies have investigated the effect of sclerostin antibody on bone density with promising results. It also has an ability to promote fracture healing, screw fixation and metaphyseal bone healing in vivo. Early clinical studies have also demonstrated that it can increase bone mineral density, whilst being safe and well tolerated by patients. Expert opinion: The data support the further investigation of this agent for the promotion of fracture healing. We aim to review the current literature and present an update on the use of this agent to promote bone formation and healing.     

Preclinical and clinical data for the use of mesenchymal stem cells in articular cartilage tissue engineering

Introduction: With an ageing population, the prevalence of osteoarthritis (OA) has increased. Mesenchymal Stem Cells (MSCs) have been proposed to be an attractive alternative candidate in the tissue engineering of articular cartilage primarily due to its abundant source, reduced cartilage donor site morbidity, and strong capacity for proliferation and potential to differentiate toward a chondrogenic phenotype. Areas covered: A current overview of human, in vivo, and in vitro evidence on the use of MSCs in cartilage tissue engineering. Expert opinion: We demonstrate robust evidence that MSCs have the potential to regenerate articular cartilage. We also identify the complexity of designing a suitable preclinical model and the challenges in considering its clinical application such as type of MSC, scaffold, culture construct and the method by which growth factors are delivered. Of great interest is further characterization of the factors that may prevent MSC-derived chondrocytes to undergo premature hypertrophy and to understand what enables the terminal developmental pathway for permanent hyaline cartilage regeneration. Despite this, there is an abundance of evidence suggesting that MSCs are a desirable cell source and will have significant impact in tissue engineering of cartilage in the future.     

Risk of cerebral venous thrombosis in oral contraceptives pills users

The aim of this study is to assess the relative risk of cerebral venous sinus thrombosis (CVST) in Oral contraceptive pills (OCP) users compared with a control group of non-hormone users.

Enhanced recognition of ischemia by three variable analysis of the exercise stress test

Background

ECG ST-segment deviations have been the standard measure of coronary artery disease (CAD) during the exercise stress test (EST). Our past research has shown other ECG variables to be significant in EST. This study evaluates the benefit of routinely combining these variables in the detection of CAD.

Methods

Sequential patients (n = 439) with suspected CAD referred for EST had their cases reviewed. Clinical and ECG variables were associated with myocardial perfusion imaging (MPI) scintigrams used to detect ischemia during maximum EST.

Results

An increase in P-wave duration was the most sensitive predictor of ischemia with a sensitivity of 64.3%, a specificity of 86.5%, and a positive predictive power (PPP) of 57.8%. ST elevation ≥ 1 mm in lead AVR had a sensitivity of 53.1%, a specificity of 78.3%, and a PPP of 41.3%. ST depression ≥ 1 mm in leads V₄–V₆ had a sensitivity of 11.2%, a specificity of 94.7%, and a PPP of 37.9%. When these variables were combined, specificity and PPP increased to 100% (p < 0.001).

Conclusions

EST evaluation solely by ST deviation fails to identify a significant portion of ischemic cases. Combinations of ΔPWD, ST elevation in AVR, and ST depression improved the identification of ischemia.     

Manufacture and characterization of an air pollutants' adsorbent from agrowastes

The by-products of some agricultural industries and activities might perform a problem as regards to their disposal. The present study is devoted to make a good use of these wastes and consequently, the solution of the disposal problem. The results of activation and characterization of date stones, residual cake after squeezing olive oil and charcoal are presented in this study. These preliminary results, which are based on original, simple and accelerated characterization criteria, reveal the validity of the used precursors to produce air pollutants' adsorbent.     

Musculoskeletal system

Diagnostic imaging has played a major role in the evaluation of patients with cancers of the bone and soft tissue. The imaging modalities have included radiography, computed tomography, magnetic resonance imaging, and bone scintigraphy. Current experience suggests that functional imaging with positron emission tomography (PET) and [F-18]fluorodeoxyglucose (FDG) may also have an important role in the imaging evaluation of patients with bone and soft tissue sarcoma, including guiding biopsy, detecting local recurrence in amputation stumps, detecting metastatic disease, predicting and monitoring response to therapy, and assessing for prognosis. Prospective studies with large patient groups will be essential to define the exact diagnostic role of FDG PET in this clinical setting, which should also include an evaluation of the cost-effectiveness and the short-term and long-term benefits in clinical decision making and management. In this article, we review the diagnostic utility of dedicated PET and PET combined with computed tomography imaging system in the evaluation of patients with bone and soft tissue malignancies.